Izalontamab brengitecan plus osimertinib for first treatment of EGFR-mutant non-small cell lung cancer
Tests izalontamab brengitecan with osimertinib in adults with untreated EGFR-mutant non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Key facts
- Where
- Baltimore, Beaumont, Beverly Hills, Boulder, Charlotte, Chicago, Dallas, Easton, Edina, Fairfax, Fort Myers, Fullerton, La Jolla, Lebanon, Memphis, Morgantown, New Brunswick, New York, Omaha, Orlando, Ottawa, Palm Bay, Portland, Saint Paul, Salt Lake City, San Antonio, Sandusky, Seattle, Silver Spring, Sioux Falls, St Louis, St. Petersburg, The Bronx, Washington D.C., West Palm Beach, and Winchester, United StatesSee the 38 sites
- Phase
- Phase 3
Where in United States
- BaltimoreBaltimore, United StatesNot yet recruiting
- BaltimoreBaltimore, United StatesNot yet recruiting
- Texas OncologyBeaumont, United StatesTaking people
- Beverly HillsBeverly Hills, United StatesNot yet recruiting
- Rocky Mountain Cancer CentersBoulder, United StatesTaking people
- CharlotteCharlotte, United StatesNot yet recruiting
- ChicagoChicago, United StatesNot yet recruiting
- Texas Oncology - DFWDallas, United StatesTaking people
- EastonEaston, United StatesNot yet recruiting
- EdinaEdina, United StatesNot yet recruiting
- FairfaxFairfax, United StatesNot yet recruiting
- FairfaxFairfax, United StatesNot yet recruiting
- Fort MyersFort Myers, United StatesNot yet recruiting
- FullertonFullerton, United StatesNot yet recruiting
- La JollaLa Jolla, United StatesNot yet recruiting
- LebanonLebanon, United StatesNot yet recruiting
- MemphisMemphis, United StatesNot yet recruiting
- MorgantownMorgantown, United StatesNot yet recruiting
- New BrunswickNew Brunswick, United StatesNot yet recruiting
- New YorkNew York, United StatesNot yet recruiting
- OmahaOmaha, United StatesNot yet recruiting
- OrlandoOrlando, United StatesNot yet recruiting
- OttawaOttawa, United StatesNot yet recruiting
- Cancer Care Centers of Brevard - RockledgePalm Bay, United StatesTaking people
- PortlandPortland, United StatesNot yet recruiting
- Saint PaulSaint Paul, United StatesNot yet recruiting
- Salt Lake CitySalt Lake City, United StatesNot yet recruiting
- Texas Oncology - San AntonioSan Antonio, United StatesTaking people
- SanduskySandusky, United StatesNot yet recruiting
- SeattleSeattle, United StatesNot yet recruiting
- Silver SpringSilver Spring, United StatesNot yet recruiting
- Sioux FallsSioux Falls, United StatesNot yet recruiting
- Washington University School of MedicineSt Louis, United StatesTaking people
- St. PetersburgSt. Petersburg, United StatesNot yet recruiting
- The BronxThe Bronx, United StatesNot yet recruiting
- Washington D.C.Washington D.C., United StatesNot yet recruiting
- West Palm BeachWest Palm Beach, United StatesNot yet recruiting
- Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.)Winchester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07680790EU 2026-526486-21-00
- Record updated
- 10 November 2026
- Original description
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapyRead full original descriptionShow less
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Inclusion: Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment; Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution); Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator; Participants must have ECOG Performance Status 0-1.
Exclusion: Participants must not have history of ILD/pneumonitis requiring treatment with steroids (≥ Grade 2), or current or suspected ILD/pneumonitis; Participants must not have unstable, symptomatic, or uncontrolled CNS metastases, including brain, leptomeningeal disease, and/or spinal cord compression; Participants must not have clinically significant cardiac disease; Other protocol-defined inclusion/exclusion criteria apply.